Provider review
Lemonaid Health review
Microdose-forward tracks for both molecules, with the visit billed apart.
The advertised figures cover medication; the provider visit is billed separately, so the total stacks.
Price as published
Compounded semaglutide microdose $199/mo · compounded tirzepatide microdose $199/mo (medication billed separately)
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
Lemonaid runs microdose-forward tracks for both semaglutide and tirzepatide on an established telehealth platform, with a brand-referral pathway where appropriate — a reasonable place to start low if platform maturity matters to you. The number to watch is the total rather than the headline: the advertised figures cover the medication and the provider visit is billed separately on this platform, so the real monthly cost stacks. There is no included registered-dietitian support, and the compounded line carries the same post-shortage regulatory and sourcing exposure as the rest of this board.
The trade-off we would want you to read first
Medication is billed separately from the visit — total cost stacks
Who it suits, and who it does not
A good fit if
- You want an established telehealth platform rather than a new operator
- You want a low-dose track for either molecule
- You want a brand referral available if compounded is not the right route
Look elsewhere if
- You are comparing on all-in cost — the visit is billed apart from the medication
- You want dietitian support included
- You want distance from post-shortage compounded sourcing risk
How the programme works
Provider visit on Lemonaid's telehealth platform, then compounded semaglutide or tirzepatide in a microdose track, with brand referral where appropriate. The advertised $199/mo figures cover the medication; the provider visit is billed separately from the medication on this platform.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Network
- Labs
- Optional
- Dietitian support
- Not included
Strengths
- Microdose-forward tracks for both semaglutide and tirzepatide
- Established telehealth platform with provider visits and a brand-referral pathway
The other trade-offs
- Compounded GLP-1s carry post-shortage regulatory and sourcing exposure
- No included registered-dietitian support
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
Lemonaid Health is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.